Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Recruiting 2Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 11Gastrointestinal 3Tumor-Agnostic 2Thoracic 2Sarcoma 2Breast 1

Conditions

Colorectal Neoplasms 318Colonic Neoplasms 90Rectal Neoplasms 82Neoplasm Metastasis 42Pancreatic Neoplasms 40Carcinoma, Non-Small-Cell Lung 35Esophageal Neoplasms 25Neoplasms 21Stomach Neoplasms 20Esophageal Squamous Cell Carcinoma 14Adenocarcinoma Of Esophagus 12Squamous Cell Carcinoma of Head and Neck 11Lung Neoplasms 11Head and Neck Neoplasms 11Colorectal Cancer Metastatic 11Breast Neoplasms 9Gastrointestinal Neoplasms 7Ovarian Neoplasms 6Anus Neoplasms 6Hereditary Sensory and Autonomic Neuropathies 5Endometrial Neoplasms 5Cholangiocarcinoma 5Carcinoma, Renal Cell 5Carcinoma, Hepatocellular 5Triple Negative Breast Neoplasms 4Salivary Gland Neoplasms 4Recurrence 4Digestive System Neoplasms 4Advanced Colorectal Cancer 4Tongue Neoplasms 3

Interventions

Gemcitabine 11pembrolizumab 10Oxaliplatin 7Nivolumab 7Irinotecan 7Fluorouracil 7Capecitabine 7durvalumab 6Sorafenib 6Leucovorin 6Cyclophosphamide 6Paclitaxel 5Ipilimumab 5tislelizumab 3poly ICLC 3lenvatinib 3fludarabine 3Sunitinib 3Radiotherapy 3Cisplatin 3Cetuximab 3130-nm albumin-bound paclitaxel 3seocalcitol 2selinexor 2pemigatinib 2futuximab 2fludarabine phosphate 2donafenib 2cemiplimab 2atezolizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Carcinoma × Cetuximab × Gastrointestinal × Clear all
NCT06835569 2026-05-06

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

Alterome Therapeutics, Inc.

Phase 1 Recruiting
188 enrolled
GastrointestinalThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Pancreatic Neoplasms, Colorectal Neoplasms

NCT07411599 2026-04-23

Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial")

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
28 enrolled
Gastrointestinal

Colorectal Cancer, Hereditary Nonpolyposis, Type 6, Carcinoma, Colorectal Neoplasms

NCT00545545 2025-03-19

Safety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma

HiberCell, Inc.

Phase 1/2 Completed
32 enrolled 23 charts
Gastrointestinal

Carcinoma, Recurrence, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡